Epithelial-mesenchymal transition (EMT) plays an important role in idiopathic pulmonary fibrosis (IPF). Astragaloside IV (ASV), a natural saponin from astragalus membranaceus, has shown anti-fibrotic property in bleomycin (BLM)-induced pulmonary fibrosis. The current study was undertaken to determine whether EMT was involved in the beneficial of ASV against BLM-induced pulmonary fibrosis and to elucidate its potential mechanism. As expected, in BLM-induced IPF, ASV exerted protective effects on pulmonary fibrosis and ASV significantly reversed BLM-induced EMT.
| INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a prototype of chronic, progressive and fibrotic lung disease. 1 Incidence of IPF has risen over time.
Although disease course is variable and somewhat unpredictable, the median survival time from diagnosis is 2-4 years. 2 IPF was typically characterized by excessive production and deposition of extracellular matrix (ECM), chronic inflammatory process, remodelling of abnormal lung tissue structure and the gradual decline of pulmonary function. 3 The current notion Myofibroblasts derived from epithelial cells by epithelial-mesenchymal transition (EMT) exhibit abnormal proliferation and ECM overproduction, resulting in the development of IPF. 4 And studies found approximately one-third of fibroblasts are of epithelial origin in pulmonary fibrosis. 5 When EMT was occurring in the lung, the E-cadherin in epithelial cells decreased and a-smooth muscle actin (a-SMA) mesenchymal cells increased. 6 EMT plays a critical role in the development of pulmonary fibrosis. The cytokine transforming growth factor-b (TGF-b) functions served as an important mediator of fibrogenesis. TGF-b1 induces the activation of fibroblasts to undergo a phenotypic transition to myofibroblasts, which are the effectors of the fibrotic state. 7 A plenty of works have identified that TGF-b1 is an important pro-fibrotic factor that has been shown to induce EMT in pulmonary fibrosis. 8 TGF-b1-induced EMT is mainly mediated by Smad-dependent or Smad-independent pathways. 9 Thus, anti-EMT pathway or the method of inhibiting of TGF-b1 signalling could provide a novel potential target for the treatment of IPF.
Astragaloside IV (ASV) is one of the major and main active substances of traditional Chinese medicinal plant astragalus membranaceus. Recently, studies on the pharmacological effect of ASV have demonstrated its antioxidant, anti-inflammatory, anti-diabetes,
anti-hypertensive, anti-asthma, and anti-fibrotic properties. 10 ASV was found to alleviate the progression of kidney fibrosis via inhibition of MAPK pathway and TGF-b/Smad signalling pathway. 11, 12 Besides, ASV could protect against TGF-b1-induced EMT by inhibiting in peritoneal mesothelial cells by promoting smad 7 expression. 13 These all indicated the great potential of the anti-fibrosis and anti-EMT activity of ASV. Bleomycin (BLM), a drug widely used as an antineoplastic, causes a dose-dependent interstitial pulmonary fibrosis. 14 BLM-induced pulmonary fibrosis is the most commonly used animal model of IPF for studying disease pathogenesis and testing of novel pharmaceutical compounds. 15 Researchers have identified that ASV could attenuate BLM-induced pulmonary fibrosis by suppressing oxidative stress and inflammation. 16 In addition, a recent study found that ASV significantly inhibited BLM-induced ECM deposition. 17 However, whether the anti-pulmonary fibrosis of ASV was associated with its inhibition of EMT during pulmonary fibrosis is still unknown.
Forkhead box O (FOXO) transcription factors are involved in multiple physiological and pathological processes, including apoptosis, ageing, proliferation, metabolism, immunity and differentiation. 18 The mammalian FOXO have 4 members: FOXO1, FOXO3, FOXO4
and FOXO6. FOXO3a are expressed in most tissues and cells, including fibroblasts. 19 Accumulation of collagen and increased expression of a-SMA is associated with FOXO3a inactivation. 20 Moreover, suppressed FOXO3a activity resulting from hyperphosphorylation of FOXO3a by Akt was found closely linked to the progression of IPF. 21 However, limited evidence linked the relationship between FOXO3a and EMT in pulmonary fibrosis.
Considering the anti-fibrotic effect of ASV in BLM-induced pulmonary fibrosis, the possible mechanisms of that effect and the characteristics of EMT in pulmonary fibrosis, we hypothesized that ASV could suppress TGF-b1-induced phosphorylation of Akt and inactivity of FOXO3a and subsequently inhibit EMT. Here, we used BLM to reproduce IPF in rats and induced EMT alveolar epithelial cells via TGF-b1 treatment to investigate the potential effects of ASV on EMT and its underlying mechanisms.
| MATERIALS AND METHODS

| Ethics statement
All of the animal procedures including housing, care and experimental protocols were approved by the Animal Care and Use Committee of Shandong University of Traditional Chinese Medicine. All procedures on the mice were performed in accordance with the guidelines from the National Institutes of Health.
| Pulmonary fibrosis model and treatment
Forty rats were randomly divided into 4 groups. Control group: the rats were given a single intratracheal instillation of 50 mL saline;
BLM group: the rats were given a single intratracheal instillation of 
| Histologic analyses and Immunohistochemistry
The pulmonary tissues were prepared by being submerged in formaldehyde solution (10%) and embedded in paraffin. The 
| Immunofluorescence
The previous procedures of immunofluorescence for lung tissues were the same as immunohistochemistry. After incubated with anti-E-cadherin or a-SMA (1:500) antibody at 4°C overnight, the sections were incubated with Alexa 488 Goat Anti-rabbit IgG and Alexa 594
Goat Anti-Rat IgG at room temperature for 1 hour. Nuclei were counterstained with DAPI, and the sections were then captured under a fluorescence microscope. For in vitro immunofluorescence, the cells were fixed with 4% paraformaldehyde for 15 minutes, and permeabilization with 0.1% Triton-X 100. After blocking with 5%
BSA for 30 minutes at room temperature, the cells were incubated with the anti-E-cadherin antibody (1:500), a-SMA antibody (1:400) and FOXO3a (1:400) at 4°C overnight. After rinsed with PBS, cells
were incubated with Alexa 594 Goat Anti-Rat IgG2A or Alexa 488
Goat Anti-rabbit IgG. All secondary antibodies were purchased from Invitrogen (Carlsbad, CA, USA) and were used at a working dilution of 1:500. 6-diamidino-2-phenylindole (DAPI) (Life Technologies Corporation) was used to identify the nucleus. The images were captured by an Nikon Eclipse 800 epifluorescence microscope with the appropriate filters.
| Measurement of oxidative stress and inflammation in lung tissues
The right lung of the rats was homogenized in 50 mmol/L PBS containing 0.5% hexadecylammonium bromide and 5 mmol/L EDTA.
After the lung extracts were centrifuged at 12 000 g for 15 minutes
at 4°C, the supernatants were acquired. For measurement of oxidative stress, the appropriate volume of supernatant was collected to determine the release of MDA, SOD and GSH-Px using Malondialdehyde (MDA) assay kit, Superoxide Dismutase (SOD) assay kit and Glutathione Peroxidase Assay Kit (Jian Cheng Biological Engineering
Institute, Nanjing, China) according to the manufacturer's instructions. To determine the inflammatory response, the levels of TNF-a and IL-6 were measured using the corresponding ELISA kit (R&D Systems, Minneapolis, MN, USA) following the manufacturer's instructions.
| RNA extraction and quantitative real-time PCR (qRT-PCR)
Total RNA was isolated using TRIzol Reagent (Takara, Shiga, Japan).
The PrimeScriptTM RT-PCR Kit (Takara) was used to process firststrand cDNA synthesis. The mRNA of COLIA1, TGF-b1 and FOXO3a were evaluated using the SYBR Green PCR Master Mix (Takara) on an iCyler iQ Real-Time PCR System (Bio-Rad Laboratories Inc., USA) according to the manufacturer's instructions with the following reaction conditions: 94°C for 2 minutes, followed by 40 cycles at 94°C for 10 seconds, 60°C for 1 minutes, and 30 seconds at 72°C. GAPDH was used as internal controls. The sequences used were listed in Table 1 . We calculated the CT values of each gene in samples and used the 2 ÀDDCt method to measure the transcript levels.
| Western blotting
Total protein was extracted from frozen lung tissue or cells using 
| Statistical analysis
Experimental results were expressed as mean AE standard deviation.
Differences were analysed by one-way ANOVA using SPASS | 4357
Software Inc., CA) was used to generate graphs. P < .05 was considered statistically significant.
| RESULTS
| ASV alleviated BLM-induced pulmonary fibrosis
Following intratracheal spray of BLM, a significant weight loss and increase in the lung wet-to-dry weight ratio were observed. But, BLM-induced weight loss and the increase in the wet-to-dry weight ratio were reversed by ASV treatment ( Figure 1A,B) . H&E and Masson's trichrome staining showed pronounced diffuse fibrosis and lymphocyte infiltration and amounts of collagen were deposited in BLM group as compared with control group. Whereas, fibrosis
showed apparent symptomatic relief in ASV treatment group compared with the BLM group ( Figure 1C ). In addition, compared with controls, the expression of collagen I mRNA and protein was also markedly increased caused by BLM. And 20 mg/mg ASV alleviated collagen deposition significantly ( Figure 1D ,E). These results suggest that ASV attenuated BLM-induced pulmonary fibrosis.
| ASV attenuated oxidative stress and inflammation in BLM-induced pulmonary fibrosis
In order to validate the anti-oxidative effects of ASV, oxidative stress was evaluated by detecting the levels of MDA, SOD, GSH-PX and inflammatory responses by the levels of TNF-a and IL-6 in pulmonary tissue. In the BLM group, the levels of MDA were significantly elevated while SOD and GSH-PX were reduced. In contrast, treatment with ASV dramatically decreased the levels of MDA and increased the levels of SOD and GSH-PX (Figure 2A-C) . As for the inflammatory responses, BLM caused great increase in TNF-a and IL-6 levels, but the addition of ASV simultaneously suppressed the release of cytokines ( Figure 2D ,E). These results indicate the inhibitory effects of ASV on BLM-induced oxidative stress and inflammation in pulmonary fibrosis.
| ASV suppressed BLM-induced EMT in pulmonary fibrosis in vivo
To investigate the occurrence of EMT during lung fibrosis, the expression levels of a-SMA and E-cadherin were analysed using 
| ASV inhibited TGF-b1-mediated hyperphosphorylation and inactivity of FOXO3a in pulmonary fibrosis
TGF-b1 plays a key role in the progression of pulmonary fibrosis.
We thus investigated whether the inhibitory effects of ASV on pulmonary fibrosis was involved in its regulation of TGF-b1 levels.
BLM instillation significantly increased TGF-b1 expression in lung tissue. As expected, we found that ASV treatment significantly alleviated BLM-induced upregulation of TGF-b1 both at mRNA and protein level ( Figure 4A,B) . We subsequently tested whether ASV was involved in the downstream target genes of TGF-b1. FOXO3a was a critical downstream integrator of TGF-b1 in human lung fibroblasts and intriguing, we identified that BLM notably downregulated the expression of FOXO3a mRNA ( Figure 4C ). Although ASV treatment didn't influence the transcription of FOXO3a, using immunohistochemistry, we found ASV significantly inhibited the decrease in FOXO3A protein caused by BLM ( Figure 4D ). Changes of FOXO3A activity were assessed by measuring the phosphorylation status of Thr32 and Ser253 of FOXO3a ( Figure 4E ). The levels of phosphorylated FOXO3a at Thr32 ( Figure 4F ) and Ser253
( Figure 4G ) were significantly higher in BLM group as compared to the control and ASV group. However, co-treatment with BLM + ASV significantly inhibited the hyperphosphorylation of FOXO3a thus to inhibit the inactivity of FOXO3a caused by BLM (Figure 4H ),
| ASV suppressed FOXO3a phosphorylation in TGF-b1-induced EMT via PI3K/Akt
It has been widely investigated that TGF-b1 can induce and promote EMT. Similarly, we found that the TGF-b1 treatment induced disappearance of intercellular junction and spindle-like appearance were Figure 6E ). Furthermore, a gain of function analysis was performed to further validated TGF-b1-induced EMT through the phosphorylation of PI3K/Akt and subsequent inactivity of FOXO3a. As shown in Figure 6F ,G, the expression levels of FOXO3a mRNA and protein were restored by transfected with a pcDNA3.1 + FOXO3a. Moreover, western blot and immunofluorescence assay showed that the expression of E-cadherin was increased, whereas a-SMA was decreased in TGF-b1 + FOXO3a group as compared to that in the TGF-b1 + vector group.
The similar trends were observed after treatment with SB431542 or LY294002 ( Figure 6H,I ). These data indicated that ASV suppressed TGF-b1/PI3K/Akt/FOXO3a-mediated EMT in pulmonary epithelial cell. The main histopathological features of IPF is aggregates of proliferating fibroblasts and myofibroblasts-fibroblastic foci-within a myxoid-appearing matrix, resulting in scarring and destruction of the lung architecture. And this fibrotic response is driven by abnormally activated alveolar epithelial cells. 23 The activated myofibroblasts, always considered transformed from epithelial cells and displayed a different phenotype as compared to normal lung fibroblasts, produce extracellular matrix proteins which contribute to the progression of IPF. 24 As expected, destroyed alveolar epithelial cells and a great accumulation of ECM were observed in BLM stimulated lungs when compared to the control and ASV-treated groups. In contrast, when treated with ASV, a natural saponin with a potential anti-fibrotic property, the above pathological changes were significantly attenuated. This was consistent with a previous study describing that ASV ameliorated BLM-induced ECM deposition and decreased the levels of hydroxyproline and type III collagen. 17 We also showed ASV decreased the level of type I collagen.
Inflammation and oxidative stress also play a pivotal role in pulmonary fibrosis. 25 Studies supported that anti-inflammation or antioxidant treatment strategies may achieved improvement in pulmonary fibrosis. 26 We found the levels of inflammatory cytokine TGF-b1 is an attractant for fibroblasts and monocytes/macrophages and stimulates these cells to synthesize the pro-inflammatory and fibrogenic cytokines. It is also an inducer of ECM production. 27 TGF-b1 was elevated after bleomycin treatment, as was consistent with previous investigations. TGF-b1 plays an important role in pulmonary fibrosis in that it mediates the differentiation of fibroblast. 28 The best-studied and central player in EMT is TGF-b1. As a result of the notion that EMT directly contributes to myofibroblast accumulation in the lung, 5,29 groups of studies tried to find efficient approaches to inhibit or reverse this progress mediated by TGF-b1. [30] [31] [32] We for the first time identified the increased TGF-b1 production was potently suppressed by ASV In conclusion, our integrated approach demonstrates that ASV treatment suppressed TGF-b1/PI3K/Akt pathway to active FOXO3a, thus to prevents EMT in BLM-induced pulmonary fibrosis ( Figure 7 ).
F I G U R E 7
Astragaloside IV protected against bleomycin-induced pulmonary fibrosis through suppressing TGF-b1-mediated EMT. Astragaloside IV inhibited TGF-b1 induced activity of PI3K/Akt pathway independent inactivity of FOXO3a in pulmonary epithelial cell F I G U R E 6 Astragaloside IV suppressed TGF-b1/PI3K/Akt induced FOXO3a inactivity to reverse EMT in A549 cells. | 4363
